HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly.
DAA
HCC
HCC recurrence
HCV
hepatitis C virus
hepatocellular carcinoma
locoregional therapy
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Jun 2021
17 Jun 2021
Historique:
received:
29
04
2021
revised:
14
06
2021
accepted:
15
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) accounts for 75-85% of primary liver malignancies, and elderlies have the highest incidence rates. Direct-acting antiviral agents (DAAs) have shown satisfying results in terms of HCV sustained viral response (SVR). However, data regarding HCC risk post-DAA-SVR is still conflicting. This study aims to consider HCC onset in moderate underlying liver disease. We conducted a retrospective study on 227 chronically infected patients (cHCV), treated with DAAs. Patients were divided into three groups: "
Identifiants
pubmed: 34204186
pii: cancers13123025
doi: 10.3390/cancers13123025
pmc: PMC8235445
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gastroenterology. 2009 Jan;136(1):138-48
pubmed: 18848939
Infect Dis Clin North Am. 2019 Dec;33(4):1045-1062
pubmed: 31668190
BMC Infect Dis. 2012 Dec 18;12:357
pubmed: 23245594
J Interferon Cytokine Res. 2020 Feb;40(2):82-91
pubmed: 31800346
Gastrointest Tumors. 2020 Apr;7(1-2):50-60
pubmed: 32399465
J Hepatol. 2016 Nov;65(5):1070-1071
pubmed: 27476768
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatocell Carcinoma. 2020 Apr 15;7:45-76
pubmed: 32346535
Int J Surg Case Rep. 2018;47:19-21
pubmed: 29704738
World J Hepatol. 2019 Jan 27;11(1):1-18
pubmed: 30705715
Expert Rev Anti Infect Ther. 2019 May;17(5):311-325
pubmed: 30856022
World J Gastroenterol. 2018 Jun 28;24(24):2582-2595
pubmed: 29962815
Liver Int. 2019 Jun;39(6):1033-1043
pubmed: 30636361
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Mod Pathol. 2010 Feb;23(2):276-83
pubmed: 19935643
Chin Clin Oncol. 2013 Dec;2(4):33
pubmed: 25841912
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Gastroenterology. 2019 Jan;156(2):477-491.e1
pubmed: 30367835
PLoS One. 2017 Jun 15;12(6):e0179096
pubmed: 28617830
Gastroenterology. 2017 Mar;152(4):911-912
pubmed: 28161225
Hepatol Res. 2020 May;50(5):535-541
pubmed: 32072721
Hepatology. 2017 Jul;66(1):167-181
pubmed: 28370287
J Hepatol. 2016 Oct;65(4):727-733
pubmed: 27349488
J Hepatol. 2018 Aug;69(2):345-352
pubmed: 29551707
Hepatol Res. 2019 May;49(5):570-578
pubmed: 30623521
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
J Hepatol. 2010 May;52(5):652-7
pubmed: 20346533
J Hepatol. 2016 Oct;65(4):856-858
pubmed: 27318327
Clin Mol Hepatol. 2015 Jun;21(2):105-14
pubmed: 26157746
PLoS One. 2018 Apr 16;13(4):e0194704
pubmed: 29659591
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Clin Infect Dis. 2015 Oct 15;61(8):1304-6
pubmed: 26082511
Curr Opin Virol. 2016 Oct;20:1-10
pubmed: 27504999
J Clin Med. 2020 Nov 25;9(12):
pubmed: 33255794
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1662-1666.e1
pubmed: 27211502
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592